Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer

Annals of Oncology

Volumn 27, Issue 6, 2016, Pages 1029-1034

  Michiels, S ^a,b,c   Pugliano, L ^c,d   Marguet, S ^a   Grun, D ^c   Barinoff, J ^e   Cameron, D ^f   Cobleigh, M ^g   Di Leo, A ^h   Johnston, S ⁱ   Gasparini, G ^j   Kaufman, B ^k   Marty, M ^l   Nekljudova, V ^m   Paluch Shimon, S ^k   Penault Llorca, F ⁿ   Slamon, D ^o   Vogel, C ^p   von Minckwitz, G ^m   Buyse, M ^q   Piccart, M ^c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c JULES BORDET INSTITUTE   (Belgium)

^d Breast International Group   (Belgium)

^e AGAPLESION MARKUS KRANKENHAUS   (Germany)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g RUSH UNIVERSITY MEDICAL CENTER   (United States)

^h ISTITUTO TOSCANO TUMORI   (Italy)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^j NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^k SHEBA MEDICAL CENTER   (Israel)

^l SAINT LOUIS HOSPITAL   (France)

^m German Breast Group   (Germany)

ⁿ CENTRE JEAN PERRIN   (France)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^q HASSELT UNIVERSITY   (Belgium)

more..

Author keywords

HER2; Lapatinib; Metastatic breast cancer; Progression free survival; Surrogate; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; LETROZOLE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ARTICLE; BREAST METASTASIS; CANCER MORTALITY; CANCER SURVIVAL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; FOLLOW UP; HUMAN; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; GENETICS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2; TRASTUZUMAB;

EID: 84974806641     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw132     Document Type: Article

References (42)

1. Torre LA, Bray F, Siegel RL et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108.
2. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
3. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 1995; 159: 19-27.
4. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
6. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
7. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009; 27: 5529-5537.
8. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-640.
9. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664-8670.
10. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218-5224.
11. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008; 26: 1987-1992.
12. Laporte S, Squifflet P, Baroux N et al. Prediction of survival benefits from progressionfree survival benefits in advanced non-small-cell lung cancer: evidence from a metaanalysis of 2334 patients from 5 randomised trials. BMJ Open 2013; 3(3): pii: e001802.
13. Mauguen A, Pignon JP, Burdett S et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol 2013; 14: 619-626.
14. Michiels S, Le Maître A, Buyse M et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 2009; 10: 341-350.
15. Oba K, Paoletti X, Alberts S et al. Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst 2013; 105: 1600-1607.
16. Paoletti X, Oba K, Bang YJ et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst 2013; 105: 1667-1670.
17. Buyse M, Michiels S, Squifflet P et al. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission. Haematologica 2011; 96: 1106-1112.
18. Sherrill B, Amonkar M, Wu Y et al. Relationship between effects on time-todisease progression and overall survival in studies of metastatic breast cancer. Br J Cancer 2008; 99: 1572-1578.
19. Petrelli F, Barni S. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. Med Oncol 2014; 31: 776.
20. Harris CA, Ward RL, Dobbins TA et al. The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 2011; 22: 1308-1317.
21. Burzykowski T, Molenberghs G, Buyse M et al. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. J R Stat Soc 2001; 50: 405-422.
22. Burzykowski T, Buyse M. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharm Stat 2006; 5: 173-186.
23. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
24. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
25. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
26. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009; 27: 1999-2006.
27. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112: 533-543.
28. Johnston S, Pippen J, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol 2009; 27: 5538-5546.
29. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26: 5544-5552.
30. Gasparini G, Gion M, Mariani L et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 2007; 101: 355-365.
31. Hackshaw A, Knight A, Barrett-Lee P, Leonard R. Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer. Br J Cancer 2005; 93: 1215-1221.
32. Ciani O, Buyse M, Garside R et al. Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer. J Clin Epidemiol 2015; 68: 833-842.
33. Lassere MN, Johnson KR, Schiff M, Rees D. Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES). BMC Med Res Methodol 2012; 12: 27.
34. IQWiG. Validity of surrogate endpoints in oncology: executive summary. IQWiG Reports. Cologne: IQWiG, 2011.
35. Lassere MN, Johnson KR, Boers M et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007; 34: 607-615.
36. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642-1649.
37. Asmis T, Berry S, Cosby R et al. Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol 2014; 21: 318-328.
38. Miles DW, Dieras V, Cortes J et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013; 24: 2773-2780.
39. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783-1791.
40. Guan Z, Xu B, DeSilvio ML et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol 2013; 31: 1947-1953.
41. Swain SM, Kim SB, Cortes J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471.
42. Peddi PF, Hurvitz SA. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol 2014; 6: 202-209.